Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $42.67M (cash outflow) fell 49.7% year over year, behind the -26.6% change in trailing-twelve-month net income. Sequentially, it fell 37.3% from the prior quarter. Over 3 fiscal years it compounded at +24.1% a year.
Context
- Net income amounted to 165.6% of revenue in FY2025, down 1180.5 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$190.87M (-33.1%) for the fiscal year ending Dec 2026, a slowdown from the -10.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$42.67M-37.3% QoQ
- Last fiscal yearDec 2025
- -$285.42M-10.5% YoY
- LTMMar 2026
- -$243.25M-26.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -49.7% | -44.1% | +5.7 pp |
| 1 year | -10.5% | -33.1% | -22.7 pp |
| 3-year CAGR | +24.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (285.42M) USD
- Year-over-year change
- +10.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (285.42M) | +10.5% |
| FY2024 | 2024-12-31 | (318.76M) | -52.3% |
| FY2023 | 2023-12-31 | (209.36M) | -40.2% |
| FY2022 | 2022-12-31 | (149.34M) | -699.1% |
| FY2021 | 2021-12-31 | 24.93M | — |
Net Income vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's LTM Mar 2026 net income of $243.25M is the 4th largest of the 11 companies compared; the peer median is $70.77M.
- Its year-over-year change of -26.6% is the 8th highest of 11, against a peer median of +32.0%.
- Net income amounts to 112.0% of revenue for SNDX, versus a peer median of 66.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $460M | +54.4% | +9.8% | 393.2% | |
| LTM Dec 2025 | $314.85M | +37.9% | +28.0% | — | |
| LTM Aug 2026 | $294.88M | +220.5% | +13.6% | 42.0% | |
| LTM Mar 2026 | $243.25M | -26.6% | +24.1% | 112.0% | |
| LTM Mar 2026 | $135.21M | +1.8% | +13.3% | — | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| LTM Mar 2026 | $88.87M | -31.7% | -6.3% | — | |
| LTM Jun 2026 | $71.19M | -60.8% | +18.5% | 67.8% | |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $59.14M | -242.2% | -44.1% | 166.4% | |
| LTM Sep 2026 | $43.31M | +168.3% | — | 16.3% | |
| Peer median (excluding SNDX) | $70.77M | +32.0% | +13.3% | 66.1% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| Deferred Income Tax | 255K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.32M | 16.02M | 30.95M | 43.03M | 47.5M |
| Change in Working Capital | (9.6M) | 1.66M | 31.86M | 13.27M | (79.32M) |
| Accounts Receivables | 0 | (3.47M) | 10.71M | (11.24M) | (36.83M) |
| Inventory | 0 | 3.47M | 0 | (366K) | (32.09M) |
| Accounts Payables | 2.16M | (1.32M) | 5.61M | 1.67M | 4.95M |
| Other Working Capital | (11.76M) | 2.98M | 15.54M | 23.21M | (15.35M) |
| Other Non-Cash Items | 187K | (2.05M) | (14.06M) | (12.45M) | (5.75M) |
| Operating Cash Flow | 29.13M | (133.68M) | (160.6M) | (274.9M) | (322.98M) |
| Capital Expenditures | (129K) | (225K) | 0 | 0 | (187K) |
| Acquisitions (Net) | 40.74K | 225K | 0 | 0 | 0 |
| Purchases of Investments | (294.72M) | (495.35M) | (354.61M) | (557.05M) | (195.81M) |
| Sales of Investments | 253.98M | 308.93M | 472.22M | 337.28M | 486.03M |
| Other Investing Activities | (40.74K) | 225K | 0 | 0 | 0 |
| Investing Cash Flow | (40.87M) | (186.19M) | 117.61M | (219.78M) | 290.04M |
| Debt Repayment | 0 | (21M) | 0 | 0 | 0 |
| Common Stock Issued | 86.34M | 181.39M | 258.09M | 9.72M | 13.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.13M | 11.86M | 6.04M | 343.65M | 0 |
| Financing Cash Flow | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.72M | (147.61M) | 221.14M | (141.31M) | (19.27M) |
| Free Cash Flow | 29M | (133.9M) | (160.6M) | (274.9M) | (323.17M) |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.